Patrick Hwu, President and CEO of the Moffitt Cancer Center, shared a post on X about recent paper published in Nature Medicine:
“Could a vaccine help prevent relapse in KRAS-mutant colorectal cancer?
- A new study in Nature reports promising Phase 1 results for ELI-002 2P, an “off-the-shelf” KRAS vaccine. It works by directing vaccine peptides into lymph nodes, where they stimulate strong CD4⁺ and CD8⁺ T-cell responses.
- In patients with minimal residual disease after surgery, those with robust T-cell responses had significantly longer relapse-free and overall survival. Some also cleared circulating tumor DNA, suggesting the vaccine helped eliminate lingering cancer cells.
- Importantly, the immune response expanded beyond KRAS to other tumor mutations – a phenomenon called antigen spreading – which may enhance long-term control of cancer.
While larger trials are needed, this approach could open a new path for treating KRAS-driven colorectal and pancreatic cancers, where current immunotherapies often fall short.”
Title: Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results
Authors: Zev Wainberg, Colin Weekes, Muhammad Furqan, Pashtoon Kasi, Craig Devoe, Alexis Leal, Vincent Chung, James Perry, Thian Kheoh, Lisa McNeil, Esther Welkowsky, Peter DeMuth, Christopher Haqq, Shubham Pant, Eileen O’Reilly
Read more:
More posts featuring Patrick Hwu on OncoDaily.
